Our findings contribute novel data showing that RAB1B may serve as a novel and important biomarker to stratify patients with advanced breast cancer for more effective treatments with specific targeted therapies aimed at the TGF-β-SMAD3 pathway. Here, SMAD3 is linked to breast carcinoma.